AAMI. See Association for the Advancement of Medical Instrumentation (AAMI)
AASK trials. See African American Study of Kidney Disease and Hypertension (AASK)
ABCD study. See Appropriate Blood Pressure Control in Diabetes (ABCD) study
abdominal pain, with peritoneal dialysis, 510
abetimus sodium (LJP 394), for lupus nephritis, 249, 250
access-related infections from hemodialysis prevention
antibacterial lumen locks, 444–445
cannula characteristics, 444
exit site cleaning/skin care, 444
insertion, 444
treatment, 445–447
acetate-free biofiltration (AFB), 410
acetazolamide, 128, 615, 643, 648
acetylcysteine, 227, 484
acid-base disorders
acid-base normal physiology, 611–612
diagnosis, 612
metabolic acidosis
contributory factors/consequences, 432
correction of, 432–433
description, 612–613
redistribution hyperkalemia from, 634
treatment, 613–615
in CKD, 614
lactic acidosis, 613–614
R T A, 614
metabolic alkalosis, 615
acid-base regulation during pregnancy, 300
Acute Dialysis Quality Initiative (ADQI), 72, 141
acute fatty liver, during pregnancy, 303, 304
acute glomerulonephritis, 81, 281
acute interstitial nephritis (AIN), 122–126
causes of, 122–124
diagnosis, 122, 124
clinical features, 122–123
treatment of, 123–126
definition/etiology/pathogenesis, 122
diagnosis, 123, 124
laboratory findings, 123, 125
acute kidney injury (AKI). See also acute tubular necrosis (ATN)
biochemical markers (potential) of, 76
epidemiology of, 72–74
etiologies of acute interstitial nephritis, 122–126
atherosclerotic renal disease, 112–114
crystalline nephropathies, 127–128
disease (classification), 123
multiple myeloma associated with AKI, 126–127
renal artery/thrombosis (RAT), 174
tumor lysis syndrome, 128–129
outcomes (diagnosis of), 75
renal replacement therapy in, 137–144
RIFLE criteria for defining, 72, 74
initiation of, 75
secondary to bisphosphonate therapy, 127
Acute Kidney Injury Network (AKIN), 72
Acute Renal Failure Trial Network (ATN) study, 141
acute tubular necrosis (ATN)
causes of, 97
from COX-2 cyclooxygenases, 288
diagnosis, 97
outcomes, 98
pathophysiology, 97–98
pharmacologic therapy (once established), 104–106
during pregnancy, 304
preventive strategies, 98–104
aminoglycosides, 98–99
amphotericin B, 99
lipid-based formulations, 100
by saline (volume expansion), 99–100
dopamine, 101–102
fénoldopam, 103–104
from ischemic/postoperative ATN, 101
loop diuretics, 101
mechanical ventilation modulation, 104
N-acetylcysteine (NAC), 101–104
from rhabdomyolysis, 100
with mannitol bicarbonate, 100–101
with saline resuscitation, 100
acetate tubulo-interstitial nephritis, 288–289, 294
acyclovir, 127, 260
as cause of crystalline nephropathies, 127
capillary lysis, 707
for reduction of varicella transmission rate, 768
allopurinol, 279, 280
aldosterone deficiency, for HIV-associated MPGN, 266
ADEMEX peritoneal dialysis trial, 479, 481
adrenocorticotropic hormone (ACTH)
for idiopathic membranous nephropathy, 166–167
for SRNS (1950s–1980s), 794
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
ADAPT study, 74
evidence, 173–174
anti-mismatch treatments
anticoagulation
isolated microscopic hematuria and proteinuria, 173
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
adult Immunoglobin A nephropathy (IgAN)
comorbidities
isolated microscopic hematuria and proteinuria, 175
with nephritic syndrome, 176
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 175–177
AED study, 768
contrast-induced nephropathy (CIN)
calcium channel blockade for ARBs, 236
ndCCBs, 238
ACEi, 218
acetazolamide, 227
antihypertensive agents, 327–328
ARIs, 216–217
race/ethnicity prevalence, 220
stages of, 232
time-dependent course of, 233
diabetes burden
for CRIEs, 145–144
for diabetes-related hypertension prevention, 435
for pediatric peritoneal dialysis, 732–736
diabetes adequacy and transport test (DiSET), 489
diabetes membranes, 142, 410–411
bicompatability of, 411, 413–415
characteristics of, 411
guidelines on characteristics/RRT modality usage, 410
importance of biophysical properties, 410
initial problems with, 410
membrane flux, 411, 415
RCT reviews, 413, 414, 415
Renal Association (UK) recommendations, 412, 419
Diabetes Morbidity and Mortality Study (DMMS), 393, 394, 411
Diabetes Morbidity Study Wave II, 404
Diagnosis Outcomes and Practice Patterns Study (DiOPPS), 21–23, 268
diabetes-related hypertension, 435
diabetes therapy
See also hemodialysis (HD);
end-stage renal disease (ESRD), 548–549,
donor (living) evaluation and selection, 545–555
evaluation for MPGN, 187, 188, 189
hemodialysis (HD), infections related to;
diabetes adequacy
successes of, 13
diabetes therapy
Delivery/adequacy, 423–429
adequacy
definition, 425
recommendations, 428
approximate equations, use of, 427
Depre-Diabetes equation, 427
Tнесен equation, 427
blood urea nitrogen (BUN) rebound of, 424, 425
dosing target, 425–426
una reduction ratio (URR), 427
diabetes
renal failure, 426, 427
residual renal clearance impact on, 426
Frequent Hemodialysis Network trial, 428–430
HEMOD study, 434, 438
NCDST study, 424, 427–428
nPCR calculations, 426
renal urea clearance (Kru), 426
spKt/V, 424, 427
ndCCBs, 415
membrane integrity/clearance changes, 455–456
disadvantages of, 455
cleaning/sterilization methods, 455
advantages of, 455
water quality issues, 454–455,viral, 453–454
risk factors,
bacterial, 453
coagulation abnormalities, 457
postoperative venous thrombosis, 546
hematuria, 551
cardiopulmonary disease, 545–546
operative/postoperative, 546
other issues
operative/postoperative, 546
self-destructive behavior, 547
postoperative kidney function, 549
growth failure, 546
renal vascular disease, 554–555
other issues
age, 554
infection/malignancy, 555
abnormalities, 546
adalimumab, 549
hemodialysis (HD), infections related to;
alkalizing agents, 779
cyclosporine, 783
leucovorin, 780–781
mycophenolate mofetil, 781
tacrolimus, 781
continuous treatment, 778
Fresenius Medical Care North America (FMCNA) system, 424
FSGS. See focal segmental glomerulosclerosis (FSGS)
fungal infections, in pediatric renal transplantation, 708
Gantolf Healthcare, dialysis center survey, 453
gorizantries, 446–446, 604, 605, 688, 512
Georgia Division of Public Health, 454
German Collaborative Glomerulonephritis Study Group, 489
Gmdna's syndrome, 615
glomerular filtration rate (GFR)
glucocorticoids
- glucocorticoid remediable aldosteronism, 202
- glucocorticoid-induced osteoporosis in pediatric CKD,
- measurement of, 208
- living kidney donor evaluation, 547–548, 552
- HRS association, 88
- estimation of, 58–61
- determinations for MN, 159
decrease of, from excretion of K+, 634
- during pregnancy, 299, 300–301
- predictive equations,
- in pediatric renal transplantation, 705
- in MPGN, 185
- measurement of, 208
- in pediatric renal transplantation, 705
- in rhabdomyolysis, 673
- in children with hypertension/CVD in CKD, 671
- hypertensive crisis in, 669
- TIPS improvement of, 93
- for stage 5 CKD, 10
- decreases in, with smoking, 36
- with fish oil, 179
- with ATM, 97
- with cyclosporine, 780
- with levamisole, 780–781
- risk factors for, 810–812
- long-term toxicity from, 211
- mechanisms of action, 810–812
- use of, in HIV, 393
- in HIV, 393
- for malignancy, 585
- for anti-CD25 vs. placebo vs. Muromonab, 188
- in children with CKD, 585
- in children with immune deficiency, 585
- antibody use for, 585–585
- vs. Muromonab, 188
- vs. steroids, 586, 587
- available evidence, 584–585, 586
- definitions, 574–575
- guidelines, 576
- growth hormone (GH) results like growth factor, 654
- growth phases of children. See under: children

HAART. See highly active antiretroviral therapy

human papillomavirus, 202

HBV-associated MPGN. See hepatitis B virus

HIV. See human immunodeficiency virus

Health Care Financing Administration. See Centers for Medicare & Medicaid Services (CMS)

Heart Outcome Prevention Evaluation (HOPE) study, 235, 239

heavy metal environmental nephrotoxins, 295

selenium, 297

solvent nephropathy, 297

microscopic hematuria, 202

hematuria
- living donor evaluation, 552–553
- microvascular, in HCV-associated MPGN, 273
- hemodialysis (HD), 361, 410–419
- See also continuous venovenous hemofiltration (CVVH)

hemodialysis (HD). See also dialysis therapy; pediatric hemodialytic vascular access for hemodialysis

- CHOICE study, 501
- contraindications, 395
- dysplasia, 395
- and CVVH, 475
- management of, 450–453
- perioperative, 435
- for hemodialysis, 450
- for hemodialysis, 431–452
- hypotension, dialysis-induced, prevention, 433
- infection susceptibility in, 441–447
- interdialytic recommendations, 459
- metabolic acidosis, correction of, 452–453
- mortality vs. peritoneal hemodialysis, 406

North America, 463
- positive results of, 464–407
- nutrition assessment/management, 435–435
dietary protein intake of, 435

lean body mass, 435

malnutrition management, 434, 435

markers of visceral protein stores, 435

RCTs, 437

subjective global assessment (SGA), 434

for older patients, 505

peritoneal dialysis vs., as RRT, 471, 472
types of catheter for, 396

filtration against endotoxin toxicity, 227

vascular access for, 592

vascular access planning, statins, and failure, 298

vs. peritoneal dialysis, for pediatric patients, 723–724

hemodialysis (HD), access-related infections, 446–447

See also dialysis therapy-related infections; nosocomial infections in dialysis patients
diagnostic criteria, 446

prevention of antibacterial lumen locks, 446–446

candida characteristics, 446

exit-site cleaning/skin care, 444

insertion of catheters, 444

sources of, 442

treatment strategies, 445–447

hemodialysis (HD), infections related to hospital acquisition of, 442

vascular access infections, 446–447

hemodialysis (HD) therapy, patient management, 451–454

Hemodialysis (HEMOD) study, 438

hemolysis, choice of, in RRT, 64

hemodynamic management (goal-directed) for ARF, 42–43

hemofiller, choice of, in RRT, 64

hemoglobin target (in CRF), 324–327

blood pressure, 327

dialysis adequacy/change in GFR, 327

hemodialysis access, 327

left ventricle size, 327

mortality/cardiovascular events, 324, 327

quality of life, 327

tumors, 327

hemofiller, 57, 219, 350, 510

hemolytic anemia, 124, 238, 273, 275, 654

hemolytic uremic syndrome (HUS), 143, 212, 303–304, 546, 579

HEMO study, 415, 416, 452, 738, 739–740

Hemodialysis (HD) nephritis, 202

osteodystrophy, 807

otolgy, 807

evidence rating and therapy recommendations, 811

natural history, 808

therapeutic efficacy of therapies, 808–810, 809, 810

hyperparathyroidism, 436

with anemia, in thrombosis events, 342

correlates linked, 444

dysphonia, 358

evaluation for pediatric use, 178

in hemodialysis patients, 664, 673

in hypertension/hyperparathyroidism management, 275

intraperitoneal, and PD catheter insertion, 726

unfractionated, for RRT/AKI anticoagulation, 162–163

"Index"
Index

hepatitis B virus (HBV) associated membranoproliferative glomerulonephritis (MPGN)
clinical manifestations, 265
transplantation issues, 454–455
hepatitis C virus (HCV)

dialysis related, 454
and diabetes mellitus, 454
and hyperfiltration, as CAN mediator, 601

diabetes mellitus and, 454
and hyperfiltration, as CAN mediator, 601

clinical manifestations, 265
for end-stage renal disease, 253
for HIVAN/collapsing glomerulopathy, 257, 258
with ACEi/ARBs, 257
renal damage caused by, 258
Diabetes

diabetes mellitus in, 49
FGF23 in, 78, 79
HIV-associated glomerulonephritis in, 258
living donor statistics, 548
systemic lupus erythematosus in, 244
HIV.

See hepatitis B and C viruses

HIV-1 infection of renal epithelium, 254–256
antiretroviral therapy, indirect effects, 259
discussion of, 259
tubular crystalluria, 259
HIV/AIDS and hyperkalemia, 620–621
HIV-associated nephropathy (HIVAN) and collapsing glomerulopathy
background/clinical manifestations, 253–254
incidence of death statistics, 254
management of, 260
pathogenesis of, 256
HIV-1 infection of renal epithelium, 254–256
host factors, 256
viral genes, 256
pathology of, 256
progression to ESRD, 255

treatment of, 257–258
HAART, 257
immunosuppressive therapy, 257
HIV Medicine Association of the Infectious Diseases Society of America, 260
Ehlen Barnett of the Donor Deport Disease Focus Group, 191
primary hyperparathyroidism; secondary hyperparathyroidism, 358, 360–363
CARE II trial, 369
RIND trial cohort, 371
treatment strategies, 360–362

calcium-based phosphate binders, 362–363
metal-based phosphate binders, 362–363
non-metal-based phosphate binders, 362–363
calcium carbonate/calcium acetate, 367
lanthanum carbonate, 365–366

dyslipidemia in, 365
sodium polystyrene sulfonate, 636
insulin, 635–636
hemodialysis, 636
phosphate-restricted diet, 363

treatment for with high glycerides, 338
risk of from ACEi/ARBs/aldosterone antagonists, 238
need for control in diabetes, 493

Primary hyperparathyroidism; secondary hyperparathyroidism, 358–360

calcium carbonate/calcium acetate, 367
lanthanum carbonate, 365–366

calcium carbonate/calcium acetate, 367
sodium polystyrene sulfonate, 636
insulin, 635–636

treatment for with high glycerides, 338
risk of from ACEi/ARBs/aldosterone antagonists, 238
need for control in diabetes, 493
idiopathic membranous

dyslipidemia in CKD;

donor (living) evaluation and

Modification of Diet in Renal Disease

Kt/V

Kimmelstiel-Wilson glomerulosclerosis, 36

kidney transplantation, predictors of outcomes, 561–570.

cardiovascular disease

urea

short-term vs. long-term graft, 562

interventions for risk reduction, 568–570

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

Kt/Vmax

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,

reliability of predictors, 562–563

HLA matching, 561–562

definitions, 561

interim for risk reduction, 568–570

renal pathology, 273–274

lupus nephritis, 184

peripheral vascular disease, 537

lipid abnormalities after, 334

lactic acidosis, 613–614

lawsuit, 366, 674

Kaplan-Meier half-life, 262

Kv, as proxy for small solute clearance, 478, 479, 480

ketogenic diet

HLA matching, 561–562

reliability of predictions, 562–563

survival advantages,
Index
pediatric Immunoglobin A nephropathy (IgAN) complications
isolated microscopic hematuria and proteinuria, 175
with nephrotic syndrome, 175
with rapidly declining GFR, 175–176
with recurrent microscopic hematuria, 174–175
with slowly progressing renal impairment, 176–177
COOPHATE study, 174
evidence, 174
immunosuppressive treatments corticosteroids, 177
cyclophosphamide (with/without azathioprine), 178–179
MSF and minocycline, 179
natural history, 171
recommendations, 171, 174
pediatric kidney transplantation epidemiology/techniques
management of chronic rejection, graft nephropathy, 707
of disease recurrence, 708
hemolytic urmic syndrome, 709
APCRO, 709
steroid-resistant nephrotic syndromes, 708–709
of infection disease CMV infections, 707
fungal diseases, 708
other viruses, 707–708
of malignancy, 709
for patient graft donor/recipient factors, 705
graft function estimation, 705
long-term, 706
short-term factors, 705
short-/middle-term, 705–706
survival outcomes/cause of death, 704
treatment adherence, 709
evidence ratings/recommendations for interventions, 717–718
French and North American reports, 704
immunosuppression regimens induction therapy, 705–706
maintenance immunosuppression, 706–707
summary of studies, 706–717
pediatric nephrotic syndrome, 713–715
diabetic nephropathy, 713–714
aortic acid diabetics, 732
heparin-bathed vs. laser-bathed dialyzers, 732
CCPS/MPFD/CAFD vial PD, 734
ALL patients, XV, corticosteroids, 732–733
isletoids, 732
associated infections
available evidence, 730
epidemiology, 727, 730
guidelines, 730
peritoneal catheter-related, 728–729, 730
preservative antibiotic interventions, 730–731
technique-related preventive strategies, 731
clinical impact/strand
available evidence, 726
clinical implications, 727
guidelines, 726
clinical implications with RRT devices, 726
comorbidities, 736
evidence ratings/recommendations, 733
hospitalization, 726
patient survival/causes of death
causes of death, 725–726
determinants, 725
PD vs. HD, 723, 725
technique survival, 726
pediatric renal osteodystrophy, 355, 358, 682–689
definitions, 683
bone histomorphometry of, 682
bone mineral density (BMD), 685–687
DHS classification of bone health, 687–689
evidence ratings/recommendations for interventions, 689
glucocorticoid-induced osteoporosis, 685–687
PTH/parathyroid hormone, 682–683
QCT assessment of bone status, 689
treatment of, 684–685, 684, 686
pediatric steroid-resistant nephrotic syndrome (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
available evidence, 707–708
causes, 704
definitions, 704, 705
epidemiology, 706–707
evidence-based recommendations, 707
indicators, 704–705
lipid level management, 707
management of infections
Chinese herbal preparations, 708
influenza vaccinations, 708
IVIG, 708
pneumococcal vaccinations, 707
prophylactic antibiotic interventions, 708
strategies for varicella-zoster, 708
thymus, 708
post-transplantation treatment challenges, 708–709
reflex, 708
secondary resistance, 706–706
thrombosis, 708–710
thrombotic, 708–710,
pediatric steroid-resistant nephrotic syndromes (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
epidemiology, 736–744
evidence-based recommendations, 744
indicators, 744–745
lipid level management, 745
management of infections
Chinese herbal preparations, 746
influenza vaccinations, 746
IVIG, 746
pneumococcal vaccinations, 746
strategies for varicella-zoster, 746
thymus, 708
post-transplantation treatment challenges, 708–709
reflex, 708
secondary resistance, 706–716
thrombosis, 708–710
thrombotic, 708–710,
pediatric steroid-resistant nephrotic syndromes (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
epidemiology, 745–746
evidence-based recommendations, 746
indicators, 746–747
lipid level management, 747
management of infections
Chinese herbal preparations, 748
influenza vaccinations, 748
IVIG, 748
pneumococcal vaccinations, 746
strategies for varicella-zoster, 746
thymus, 746
post-transplantation treatment challenges, 746–748
reflex, 746
secondary resistance, 746–747
thrombosis, 708–710
thrombotic, 708–710,
pediatric steroid-resistant nephrotic syndromes (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
epidemiology, 747–748
evidence-based recommendations, 748
indicators, 748–749
lipid level management, 749
management of infections
Chinese herbal preparations, 750
influenza vaccinations, 750
IVIG, 750
pneumococcal vaccinations, 746
strategies for varicella-zoster, 750
thymus, 750
post-transplantation treatment challenges, 708–709
reflex, 708
secondary resistance, 706–716
thrombosis, 708–710
thrombotic, 708–710,
pediatric steroid-resistant nephrotic syndromes (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
epidemiology, 749–750
evidence-based recommendations, 750
indicators, 750–751
lipid level management, 751
management of infections
Chinese herbal preparations, 752
influenza vaccinations, 752
IVIG, 752
pneumococcal vaccinations, 746
strategies for varicella-zoster, 752
thymus, 752
post-transplantation treatment challenges, 708–709
reflex, 708
secondary resistance, 706–716
thrombosis, 708–710
thrombotic, 708–710,
pediatric steroid-resistant nephrotic syndromes (SRNS), 656–657
for slow mental changes (MCD)-induced SRNS
epidemiology, 751–752
evidence-based recommendations, 752
indicators, 752–753
lipid level management, 753
management of infections
Chinese herbal preparations, 754
influenza vaccinations, 754
IVIG, 754
pneumococcal vaccinations, 746
strategies for varicella-zoster, 754
thymus, 754
post-transplantation treatment challenges, 708–709
reflex, 708
secondary resistance, 706–716
thrombosis, 708–710
thrombotic, 708–710,
Index
Index

vascular access for hemodialysis
as Achilles heel, 395–396
AVF/AVG failure, pharmacological prevention (RCTs), 465–466
cuffed CRB prevention (RCTs), 464–465
dialysis-related infections, 442–443
infections eradicated, 442–443
screening/access survival
blood flow screening (RCTs), 460–461
DU stenosis (RCTs), 461–462
other techniques, 462–463
vascular access infections, 442–443
vascular access planning for hemodialysis
evidence for primary AVF, 395–396
use of tunneled cuffed cannulas, 398
vascular intimal hyperplasia, 599
vasodilator in the Management of Acute Congestive Heart Failure trial, 84
vasopressin, 37, 91, 119, 373–375, 401–403, 415, 734, 736
left VH as predictor of CVD in adults, 678
monitoring for, 204
residual renal function (RRF) and, 480
warfarin (ndCCB), 238
plus trandolapril (VeraTran), 240
for slowing progression of kidney disease, 516
vasoconstrictive reflux (VUR), in pediatric patients, 751–753
clinical spectrum, 751
definition and diagnosis, 751
as inherited trait, 751
management, 751, 753
prognosis, 751
screening, 751
Veterans Administration Health Affairs, 563
vismodegib, 794
vital infections related to dialysis, 453–454
hepatitis B and C, 453–454
hepatitis GB virus C, 454
hepatitis G-virus, 454
West Nile Virus, 454
vascular protein store markers assessment, in hemodialysis patients, 455
vitamin D deficiency for MB and ESRD
definition/epidemiology, 356–357
1,25(OH)2-vitamin D3, 356, 357, 358
outcome determinations, 358–359
supplementation for, 357–359
25(OH)-vitamin D deficiency, 357, 358–360
deficiency in Fanconi disease, 287
impaired synthesis in renal osteodystrophy, 485
for pediatric renal osteodystrophy, 485
plasminogen D3 conversion, 365
relationships with calcium/phosphorus/PTH, 514
volume regulation during pregnancy, 500
warfarin, 178, 179
with azathioprine, dipyridamole, steroids, for MPGN, 180–181
evaluation for MPGN, 197, 189
for DRS, 480
low-dose, for AAV, 463–464
for pediatric DDS, 769
for prevention of RVT/AVG failure, 465, 464
War Nephritis. See acute renal failure (ARF)
water control/quality issues in dialysis-related infections, 454–455, 456, 457
West Nile Virus, 454